Protecting our Pharmaceutical Supply Chain from China Act of 2022

Summary

Protecting o ur Pharmaceutical Supply Chain from China Act of 2022 This bill requires the federal government to maintain a registry of certain foreign-sourced drugs, prohibits federal health care programs from purchasing drugs containing ingredients manufactured in China, requires drugs to be labeled for country of origin, and offers domestic manufacturing facility tax incentives. The Food and Drug Administration shall maintain (1) a list of foreign-sourced drugs and active ingredients that are critical for consumer health and safety, and (2) another list identifying such drugs that are produced exclusively in China or use ingredients produced in China. The bill phases in a restriction on federal health care programs purchasing drugs with active ingredients manufactured in China. By January 1, 2024, such programs may not purchase a drug with any active ingredients from China. The Department of Health and Human Services may issue a waiver for an agency or program that is unable to meet this requirement, but no waiver may apply to drugs purchased in or after 2026. Each drug must have labeling listing the country of origin of each active ingredient, and a drug without this labeling shall be deemed misbranded. The bill allows 100% tax expensing for qualified pharmaceutical and medical device manufacturing property placed in service between 2020 and 2026.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 17 March 2022

   Introduced

   Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Veterans' Affairs, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

   Source: IntroReferral

2. 17 March 2022

   Introduced

   Introduced in House

   Source: IntroReferral

3. 17 March 2022

   Introduced

   Introduced in House

   Source: IntroReferral

4. 18 March 2022

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

5. 28 March 2022

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

Votes

No vote records are attached yet.

Versions

• Introduced in House · 17 March 2022 · Official file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 17 March 2022

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 17 March 2022

  ViewDownloadOpen at official source

• Introduced in House

  summary · EN · 17 March 2022

  Open at official source

Sponsors

• Mike Gallagher · R · Sponsor
• Elise Stefanik · R · Sponsor
• Liz Cheney · R · Sponsor
• Ted Budd · R · Sponsor
• Jefferson Van Drew · R · Sponsor
• Vicky Hartzler · R · Sponsor
• Bill Posey · R · Sponsor
• Rep. Harshbarger, Diana [R-TN-1] · R · Cosponsor
• Brian Babin · R · Cosponsor
• · hsvr00 · Standing
• · hsif00 · Standing
• · hsas00 · Standing
• · hswm00 · Standing

Related records

• related to → ABC Safe Drug Act
• related to → Protecting our Pharmaceutical Supply Chain from China Act of 2021